Journal article · 2023 · Open access
P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims
Value in Health, 26(6), S9 · Published 1 June 2023 · DOI 10.1016/j.jval.2023.03.051
In brief
“P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims” is a 2023 journal article by C. Desvignes-Gleizes and 4 co-authors, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access: the full text is free to read at Value in Health.
- Citations
- 0
- Authors
- 5
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Desvignes-Gleizes, C., Kraft, N., Desruol‐Allardin, S., Bothorel, S., & Sherafat‐Kazemzadeh, R. (2023). P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims. Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.051
MLA 9
Desvignes-Gleizes, C., et al. “P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims.” Value in Health, vol. 26, no. 6, 2023, p. S9. https://doi.org/10.1016/j.jval.2023.03.051.
Chicago
Desvignes-Gleizes, C., N. Kraft, Sandra Desruol‐Allardin, Sonia Bothorel, and Roya Sherafat‐Kazemzadeh. 2023. “P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims.” Value in Health 26 (6): S9. https://doi.org/10.1016/j.jval.2023.03.051.
Harvard
Desvignes-Gleizes, C. et al. (2023) ‘P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims’, Value in Health, 26(6), p. S9. doi:10.1016/j.jval.2023.03.051.
IEEE
C. Desvignes-Gleizes, N. Kraft, S. Desruol‐Allardin, S. Bothorel, and R. Sherafat‐Kazemzadeh, “P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims,” Value in Health, vol. 26, no. 6, p. S9, 2023, doi: 10.1016/j.jval.2023.03.051.
BibTeX
@article{desvignesgleizes2023patient,
title = {{P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims}},
author = {Desvignes-Gleizes, C. and Kraft, N. and Desruol‐Allardin, Sandra and Bothorel, Sonia and Sherafat‐Kazemzadeh, Roya},
journal = {Value in Health},
year = {2023},
volume = {26},
number = {6},
pages = {S9},
doi = {10.1016/j.jval.2023.03.051},
url = {https://doi.org/10.1016/j.jval.2023.03.051}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- patient-reported outcomes
- clinical trial endpoints
- cancer clinical trials
- regulatory approval
- FDA
- EMA
- regulatory differences
- drug approval
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
Desvignes-Gleizes, C., Kraft, N., Desruol‐Allardin, S., Bothorel, S., & Sherafat‐Kazemzadeh, R. (2023). P39 Patient-Reported Outcomes As Endpoint in Oncology Trials: An Analysis of FDA and EMA Claims. Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.051
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Value in Health: sign in and open the PDF from this page.
Who wrote this paper?
C. Desvignes-Gleizes, N. Kraft, Sandra Desruol‐Allardin, Sonia Bothorel, Roya Sherafat‐Kazemzadeh.
What is the DOI of this paper?
10.1016/j.jval.2023.03.051, permanently at https://doi.org/10.1016/j.jval.2023.03.051. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.